Medication Monitor

Generic Name (Trade Name—Company)
April 1, 2011

Varicella zoster vaccine, live, attenuated

Approved for use in younger patients


Prevention of herpes zoster (shingles) in patients 50 to 59 years of age

Zostavax was originally approved for patients 60 years and older. Data from a placebo-controlled, double-blind study involving 22,439 patients who were 50 to 59 years of age showed that administration of the vaccine reduced the risk of developing zoster by 69.8% over a median monitoring period of 1.3 years. Injection-site reactions were the most commonly observed adverse events in this patient population.